Melanocortin therapies to resolve fibroblast-mediated diseases. (2022)
Attributed to:
Harnessing the Melanocortin System (MCS) to moderate inflammation and enhance healthy ageing
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3389/fimmu.2022.1084394
PubMed Identifier: 36793548
Publication URI: http://europepmc.org/abstract/MED/36793548
Type: Journal Article/Review
Volume: 13
Parent Publication: Frontiers in immunology
ISSN: 1664-3224